Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immuron Ltd.
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
Given effect corticosteroids have on patients, US FDA asks whether they can be excluded from use in alcoholic hepatitis clinical trials.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With an average return of 33.2% in 2017, the number of biopharma IPOs that launched last year rose to 42 after falling to 30 in 2016 compared with 62 in 2015. Following a rough fourth quarter for biopharma stocks, will the IPO momentum continue in 2018?
Drug Discovery Tools
- Natural Products
- Molecular Diversity